Baird Financial Group
RARE icon

Baird Financial Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Baird Financial Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,553
Closed -$215K – 1912
2021
Q4 		$215K Sell
2,553
-10
-0.4% -$814 ﹤0.01% 1798
2021
Q3 		$231K Buy
+2,563
New +$232K ﹤0.01% 1761

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baird Financial Group's RARE Position: Q1 2022 in Review

Baird Financial Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2022, closing a stake of 2,553 shares — an estimated $215K sold.

Baird Financial Group first reported a position in RARE in Q3 2021 and held it in 2 quarters. The position peaked at $231K in Q3 2021. 239 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

  • Baird Financial Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • Baird Financial Group sold 2,553 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $215K.
  • Baird Financial Group first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and held it in 2 quarters.
  • Baird Financial Group's Ultragenyx Pharmaceutical position peaked at $231K in Q3 2021.
  • 239 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Baird Financial Group's 13F filing for Q1 2022, filed 13 May 2022.